MET10 Antibody

What is the MET10 antibody and what does it target?

The MET10 antibody is a rabbit polyclonal antibody that targets the C-terminal region (amino acids 444-472) of human Methyltransferase-like protein 16 (METTL16), also known as Methyltransferase 10 domain-containing protein (METT10D). This antibody recognizes a KLH conjugated synthetic peptide from the C-terminal region of human MET10 . METTL16 functions as an RNA N6-methyltransferase that methylates adenosine residues at the N6 position in a subset of RNAs and plays a critical role in S-adenosyl-L-methionine homeostasis by regulating the expression of MAT2A transcripts .

What are the validated applications for MET10 antibody?

Based on current research protocols, the MET10 antibody has been validated for several experimental applications:

The antibody has been specifically tested and confirmed to react with human and mouse samples . When designing experiments, researchers should validate reactivity in other species before proceeding with full-scale studies.

How should the MET10 antibody be stored for optimal stability?

For optimal stability and performance, the MET10 antibody should be maintained refrigerated at 2-8°C for short-term storage (up to 2 weeks). For long-term storage, the antibody should be stored at -20°C in small aliquots to prevent freeze-thaw cycles, which can significantly degrade antibody quality and performance . The antibody is typically supplied in PBS with 0.09% (W/V) sodium azide as a preservative, which helps maintain stability during storage .

How can MET10 antibody be used to study RNA methylation mechanisms?

The MET10 antibody can be employed as a powerful tool to investigate the mechanisms of RNA methylation mediated by METTL16. METTL16 has been shown to methylate a limited number of RNAs, requiring both a specific 5'UACAGAGAA-3' nonamer sequence and a particular RNA structure, distinguishing it from the METTL3-METTL14 heterodimer .

Research approaches include:

• Using the antibody in RNA immunoprecipitation (RIP) assays to identify RNA targets of METTL16

• Employing Western blot analysis to assess METTL16 expression levels in different tissues or under various experimental conditions

• Performing immunohistochemistry to localize METTL16 in tissues and assess its expression patterns in different physiological or pathological states

When studying METTL16-mediated methylation, researchers should consider that METTL16 plays a key role in S-adenosyl-L-methionine homeostasis through N6-methylation of MAT2A mRNAs, which alters the splicing of MAT2A transcripts .

What are the key considerations for using the MET10 antibody in immunohistochemistry?

When using the MET10 antibody for immunohistochemistry on paraffin-embedded tissues (IHC-P), researchers should consider several methodological factors:

• Optimal dilution: The recommended dilution for IHC-P is 1:100, though this may require optimization based on your specific sample type and detection system

• Antigen retrieval: Since the antibody targets the C-terminal region (444-472 aa) of METTL16, proper antigen retrieval is crucial for exposing this epitope that might be masked during fixation

• Controls: Include both positive controls (tissues known to express METTL16) and negative controls (omitting primary antibody) to validate specificity

• Signal amplification: For low-abundance targets, consider using signal amplification methods such as tyramide signal amplification (TSA)

Similar to approaches used with other antibodies like those targeting MET receptor, a tiered validation approach should be employed to ensure specificity and reproducibility of results .

How can the MET10 antibody be used in conjunction with other research tools to study epitranscriptomic regulation?

The MET10 antibody can be integrated with complementary research tools to comprehensively investigate epitranscriptomic regulation mediated by METTL16:

• Combining with m6A-seq: Use the MET10 antibody to immunoprecipitate METTL16 and correlate its binding sites with m6A modifications identified by m6A-seq

• CRISPR-Cas9 systems: Validate antibody specificity by detecting the presence/absence of signal in CRISPR-knockout models of METTL16

• Mass spectrometry validation: Confirm the methyltransferase activity of immunoprecipitated METTL16 using mass spectrometry to identify methylated nucleosides

• Proximity ligation assays: Identify protein interaction partners of METTL16 to elucidate regulatory complexes

This multi-modal approach allows researchers to establish structure-function relationships, similar to how antibodies have been used to identify truncated isoforms of other receptors and dissect different epitopes .

What are the critical controls needed when using MET10 antibody in Western blotting experiments?

When designing Western blot experiments with the MET10 antibody, researchers should implement several critical controls:

• Positive control: Include a lysate from cells/tissues known to express METTL16 (calculated MW: 63621 Da)

• Negative control: Use lysates from METTL16 knockout cells or tissues where available

• Loading control: Include an antibody against a housekeeping protein (e.g., GAPDH, β-actin) to normalize expression levels

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide to confirm specificity

• Molecular weight marker: Ensure proper identification of the target band (expected at approximately 63.6 kDa)

To optimize Western blot protocol, use the recommended dilution of 1:2000 as a starting point and adjust based on signal intensity and background .

How can researchers optimize immunoprecipitation protocols using the MET10 antibody?

Optimizing immunoprecipitation (IP) protocols with the MET10 antibody requires careful consideration of several parameters:

• Antibody amount: Start with 2-5 μg of antibody per 500 μg of protein lysate, then optimize based on results

• Lysis buffers: Choose a buffer that maintains protein-protein interactions without disrupting the epitope (amino acids 444-472 of METTL16)

• Incubation conditions: Typically, overnight incubation at 4°C with gentle rotation yields optimal results

• Washing stringency: Balance between removing non-specific interactions and maintaining true interactions

• Elution conditions: Consider both denaturing (SDS-based) and non-denaturing (peptide competition) elution methods based on downstream applications

Unlike methods developed for antibodies against cell surface receptors like MET/HGFR, where accessibility of the epitope is different, METTL16 IP protocols may require more aggressive cell lysis conditions to access this intracellular protein .

How should researchers interpret non-specific bands when using the MET10 antibody in Western blot?

When analyzing Western blot results with the MET10 antibody, researchers may encounter non-specific bands. Proper interpretation involves systematic analysis:

• Expected molecular weight: The calculated molecular weight of METTL16 is 63621 Da ; the primary band should appear near this size

• Post-translational modifications: Additional higher molecular weight bands may represent phosphorylated, ubiquitinated, or other modified forms of METTL16

• Alternative splicing: Lower molecular weight bands may represent splice variants of METTL16

• Degradation products: Multiple lower bands in a ladder pattern may indicate protein degradation during sample preparation

• Cross-reactivity: Persistent bands in knockout controls suggest cross-reactivity with related proteins

To mitigate non-specific binding, researchers can try increasing the antibody dilution (beyond 1:2000) , using different blocking agents, or implementing more stringent washing procedures.

What approaches can be used to validate the specificity of MET10 antibody in new experimental systems?

When introducing the MET10 antibody to new experimental systems, validation of specificity is crucial:

This tiered approach ensures reliable results across different experimental conditions and resembles validation approaches used for other research antibodies .

How can the MET10 antibody be used to study the role of METTL16 in cancer progression?

Given the emerging role of RNA methylation in cancer biology, the MET10 antibody can be utilized to investigate METTL16's potential contributions to cancer progression:

• Expression analysis: Perform IHC-P (1:100 dilution) on tumor microarrays to correlate METTL16 expression with clinical outcomes

• Mechanistic studies: Use the antibody to assess how METTL16-mediated RNA methylation affects oncogene expression through altered RNA splicing, particularly of MAT2A transcripts

• Biomarker development: Evaluate METTL16 as a potential diagnostic or prognostic biomarker through quantitative analysis of expression patterns

• Therapy response prediction: Investigate whether METTL16 expression levels correlate with response to specific cancer therapies

This research direction parallels approaches used with other antibodies in cancer research, like those targeting the MET/HGF receptor, which have been employed as both diagnostic tools and potential therapeutic targets .

What are the considerations for using MET10 antibody in multiplexed imaging systems?

When incorporating the MET10 antibody into multiplexed imaging systems, researchers should address several technical considerations:

• Antibody compatibility: Ensure compatibility with other primary antibodies (species, isotype, detection system)

• Sequential staining protocols: Develop sequential staining approaches when antibodies have cross-reactivity concerns

• Signal separation: Utilize appropriate fluorophores with distinct spectral properties to minimize bleed-through

• Epitope stability: Verify that harsh stripping or elution buffers used in cyclic immunofluorescence don't damage the METTL16 epitope (aa 444-472)

• Signal normalization: Implement computational methods to normalize signal intensities across different antibody stains

Unlike antibodies against cell surface receptors like MET/HGFR, the MET10 antibody targets an intracellular protein, requiring appropriate permeabilization protocols in multiplexed imaging workflows .

What future directions might enhance the utility of MET10 antibody in research?

Several emerging approaches could significantly expand the research applications of the MET10 antibody:

• Development of monoclonal versions: Creating monoclonal variants targeting the same epitope could enhance reproducibility and specificity

• Cross-platform validation: Comprehensive validation across multiple techniques (ChIP-seq, RIP-seq, etc.) would broaden utility

• Application-specific conjugates: Direct conjugation to fluorophores, enzymes, or magnetic beads would streamline workflows

• Integration with single-cell technologies: Adapting protocols for single-cell analysis would enable high-resolution studies of METTL16 function

• Therapeutic target exploration: Investigating whether METTL16 could serve as a therapeutic target in diseases with dysregulated RNA methylation